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Abstract: Pramlintide is a synthetic version of the naturally occurring pancreatic peptide called 
amylin. Amylin and pramlintide have similar effects on lowering postprandial glucose, lower-
ing postprandial glucagon and delaying gastric emptying. Pramlintide use in type 1 and insulin 
requiring type 2 diabetes mellitus (DM) is associated with modest reductions in HbA1c often 
accompanied by weight loss. Limited data show a neutral effect on blood pressure. Small studies 
suggest small reductions in LDL-cholesterol in type 2 DM and modest reductions in triglycerides 
in type 1 DM. Markers of oxidation are also reduced in conjunction with reductions in post-
prandial glucose. Nausea is the most common side effect. These data indicate that pramlintide 
has a role in glycemic control of both type 1 and type 2 DM. Pramlintide use is associated with 
favorable effects on weight, lipids and other biomarkers for atherosclerotic disease.
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Introduction
The beneﬁ  ts of glycemic control on reducing the risk for microvascular complications 
are now quite well established from both observational data sets and intervention 
trials (DCCT Research Group 1993, 2001; DCCT/EDIC Research Group 2000; 
UKPDS Research Group 1998a,b). Several factors limit the ability to normalize 
blood sugar in diabetic patients. These include the inability to target each of 
the pathophysiological defects associated with hyperglycemia, side effects of 
medication, contraindications to use of selected medications (eg, renal dysfunction, 
heart failure), risks for hypoglycemia, and the common association of intensive 
glycemic control with a risk for weight gain. This article will focus on the use of 
pramlintide, a synthetic version of amylin (a glucose lowering hormone) and its role 
in the management of diabetes. Pramlintide targets mainly postprandial glycemic 
excursion, and as such the effects on mean glycemic control as determined by HbA1c 
are modest. However, there are very few contraindications, hypoglycemia risk is 
low, and absence of weight gain (or even weight loss) typiﬁ  es its use. This article 
will review the development of pramlintide, its use in diabetes mellitus (DM) as 
a glycemic control agent, and its effects on body weight as well as current limited 
data on blood pressure, lipids, and some oxidation biomarkers that are associated 
with cardiovascular disease risk.
Amylin physiology and pathophysiology
Amylin is a 37 amino acid polypeptide that is co-secreted in equimolar quantities with 
insulin from pancreatic β cells (Uwaifo and Ratner 2005; Young 2005). Of note is Vascular Health and Risk Management 2008:4(2) 356
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the fact that amylin secretion is diminished (or even absent) 
in patients with types 1 and 2 diabetes (Baron et al 2002). 
Furthermore, the degree of insulin deﬁ  ciency generally 
correlates with the degree of amylin deﬁ  ciency (Young 
2005). Amylin is metabolized by proteolytic degradation in 
the kidney (Young 2005).
Amylin has glucose-lowering effects in both animals and 
humans. Uwaifo and Ratner (2005) have summarized the 
effects (with their corresponding extensive references) as 
follows: (1) suppression of endogenous glucagon production, 
especially in the postprandial state; (2) consequent reduction 
of postprandial hepatic glucose production; (3) reduction in 
gastric emptying time; (4) centrally mediated induction of 
satiety; and (5) reduction in postprandial glucose levels.
Because native amylin was characterized as “glue like,” 
somewhat unstable as a compound in solution, modifying 
amylin to a compound with more manageable physical 
properties resulted in the development of pramlintide. 
Pramlintide has similar physiologic effects as native amylin 
(see Table 1), but could be produced as the stable injectible 
product now available for clinical use as Symlin™ (Thompson 
et al 1998; Vella et al 2002; Kleppinger and Vivian 2003). 
Physiologic effects of native amylin and the synthetic 
analogue, pramlintide, include suppression of postprandial 
glucagon and slowing of gastric emptying. Insulin deﬁ  ciency 
and glucagon excess have both been shown to contribute to 
postprandial glycemic excursion (Shah et al 2000). Thus the 
effects of pramlintide on postprandial glycemic control appear 
to be at least partially mediated by restoring appropriate 
prandial reduction in glucagon (Gedulin et al Young 1997; 
Fineman et al 1999b, 2002a; Levetan et al 2003; Heptulla 
et al 2005). It does not appear that this prandial suppression 
of glucagon by pramlintide impedes the glucagon response to 
hypoglycemia. Amiel evaluated each of the counter-regulatory 
hormones triggered by hypoglycemia (catecholamines, growth 
hormone, cortisol, and glucagon) and found that pramlintide 
administration did not attenuate the effects of any of them, 
including glucagon (Amiel et al 2005).
Glycemic control in diabetes 
mellitus
Pramlintide use in type 1 DM
The preprandial administration of pramlintide as an adjunct 
to preprandial insulin therapy leads to a substantial reduction 
in postprandial hyperglycemia (Kolterman et al 1995, 1996; 
Thompson et al 1997a,b; Nyholm et al 1999; Weyer et al 
2001; Weyer et al 2003; Heptulla et al 2005; Hoogwerf 2006) 
as a result of suppressing postprandial hyperglucagonemia 
(Nyholm et al 1999; Weyer et al 2001; Fineman et al 2002b) 
as well as delaying gastric emptying (Kong et al 1998; Vella 
et al 2002). Clinical studies have shown that reduction in 
postprandial glucose excursion translates into signiﬁ  cant and 
sustained reductions in HbA1c (see Table 2) (Fineman et al 
1999a; Gottlieb et al 2000; Whitehouse et al 2002; Ratner 
et al 2004; Edelman et al 2006). In a multicenter study of 
480 patients with type 1 DM, Whitehouse and colleagues 
showed that treatment with pramlintide led to a mean reduc-
tion in HbA1c of 0.67% from baseline to week 13 that was 
signiﬁ  cantly (p   0.0001) greater than the placebo reduction 
(0.16%); a signiﬁ  cant placebo-corrected treatment difference 
was sustained through week 52 (p = 0.007) (Whitehouse et al 
2002). This was not accompanied by an increased overall 
event rate of severe hypoglycemia. Ratner and colleagues 
showed that the addition of pramlintide 60 µg 3 times daily 
(tid) or 4 times daily (qid) to insulin led to signiﬁ  cant reduc-
tions in HbA1c of 0.29% (p   0.011) and 0.34% (p   0.001) 
respectively, compared with a 0.04% reduction in placebo 
group, over 52 weeks (Ratner et al 2004). In this study, the 
proportion of pramlintide vs placebo-treated patients who 
achieved an HbA1c of  7% was 3-fold higher. This was 
achieved without an increase in concomitant insulin use in 
the pramlintide-treated group. In a subset of these patients 
combined with patients from other studies in whom HbA1c 
values were  8.0% at entry, favorable effects on glycemic 
control were also demonstrated (Ratner et al 2005).
Table 1 Summary characteristics of amylin and pramlintide
Amylin
37 amino acid compound
Co-secreted with insulin from beta cells
Deﬁ  cient in type 1 and type 2 DM
Renal clearance
Physiological effects
 1.    Suppression of endogenous glucagon production (especially in the  
postprandial state)
  2. Reduction in postprandial hepatic glucose production
  3. Reduction in gastric emptying time
  4. Centrally mediated induction of satiety
  5. Reduction in postprandial glucose levels
Pramlintide
Synthetic analogue of amylin (3 amino acid substitutions with proline for 
native amino acids
Subcutaneous administration
Effects in type 1 and type 2 DM
  1. Reduction in prandial glucose
  2. Reduction in HgbA1c
  3. Reduction in prandial glucagon
  4. Slowed gastric emptying
 5.  Weight  lossVascular Health and Risk Management 2008:4(2) 357
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Several studies have assessed the effect of pramlintide 
on weight control in patients with type 1 DM. In the study 
reported by Whitehouse, the greater HbA1c reduction in the 
pramlintide-treated group was associated with an average 
weight loss (rather than commonly observed weight gain 
with improved glycemic control). Weight loss was signiﬁ  cant 
from week 13 onward (Whitehouse et al 2002). Ratner also 
reported that greater reduction in HbA1c with pramlintide 
was accompanied by a signiﬁ  cant reduction in body weight 
from baseline to week 52 of 0.4 kg in the 60 µg tid (p   0.027) 
or qid (p   0.040) pramlintide treatment groups, compared 
with a 0.8 kg gain in body weight in the placebo group 
(Ratner et al 2004). A 29-week, double-blind, randomized, 
placebo-controlled study of 296 patients with type 1 DM 
showed that pramlintide treatment signiﬁ  cantly reduced 
weight (pramlintide –1.3 ± 0.30, placebo +1.2 ± 0.30 kg; 
p   0.0001) despite equivalent HbA1c reductions relative 
to placebo (Edelman et al 2006).
The most commonly reported adverse effects associated 
with pramlintide use in type 1 DM were nausea, anorexia, 
and hypoglycemia in these studies. These adverse effects 
occurred more often during the initiation of therapy and 
were usually mild to moderate in nature (Weyer et al 2001; 
Whitehouse et al 2002; Ratner et al 2004, 2005; Ryan et al 
2005; Edelman et al 2006; Nogid and Pham 2006). Pramlint-
ide treatment improved patient satisfaction in some studies 
despite requiring additional injections (Want 2006; Marrero 
et al 2007).
Pramlintide use in type 2 DM
In type 2 DM pramlintide has been approved for use as an 
adjunct to preprandial insulin with or without concurrent met-
formin or sulfonylurea therapy in patients with sub-optimal 
glucose control. This approval was based on the ability of 
pramlintide to improve glucose control when added to insulin 
therapy and has been supported by both short and long term 
studies (Ratner et al 2002, 2005; Whitehouse et al 2002; 
Hollander et al 2003a, 2004; Gottlieb et al 2007) (see Table 
3). Ratner conducted a multi-centre randomized clinical 
trial (RCT) of 1 year duration and showed that addition 
of pramlintide to meal time insulin resulted in a reduction 
in a mean HbA1c of 1% by 13 weeks at the 150 µg dose 
(Ratner et al 2002). This effect was sustained at the end of 
1 year with a mean reduction of HbA1c by 0.6% in both 
treatment arms (75 µg, 120 µg) compared with the placebo 
arm. Another study in type 2 DM demonstrated a similar 
sustained reduction in A1c of 0.62% at the 120 µg dose as 
compared to placebo (p   0.05) (Hollander et al 2003b). In 
both long-term studies, a signiﬁ  cantly greater proportion of 
patient in the treatment arm were able to achieve a target 
HbA1c of  8%. A pooled post-hoc analysis of 2 large 
RTC of approximately 500 patients showed that treatment 
of pramlintide with 120 µg bid demonstrated a signiﬁ  cant 
placebo-corrected reduction of HbA1c of 0.41% at 26 weeks 
(p   0.0001) (Hollander et al 2004). In a study similar to the 
analysis in type 1 DM (Ratner et al 2005), Hollander also 
reported favorable glycemic effects in type 2 DM patients 
Table 2 Studies of pramlintide use in patients with type 1 DM
Study Patients (n) Study design Duration (weeks) Pramlintide dose HbA1c ∆ (%) Wt ∆ (kg)
(Fineman et al 1999a) 586 DB, PC, multicenter 26 60 µg tid or –0.2 (p = sign.) –1.6
90 µg bid-tid –0.1 (NS) –0.7
or placebo –0.1 (NS) –1.6
+0.1 +0.3
(NS)
(Gottlieb 2000) 479 DB, PC, multicenter 52 60 µg tid-qid or 
placebo
–0.4/–0.3
NR
–1.4/–1.7
NR
(p = sign.) (p = sign.)
(Whitehouse 2002) 480 DB, PC, multicenter 52 30–60 µg qid or 
placebo
 –0.39
–0.12
–0.5a
+1.0a
(p = 0.0071) (p   0.001)
(Ratner et al 2004) 479 DB, PC, multicenter 52 60 µg tid-qid or 
placebo
–0.29/–0.34
–0.04
–0.4/–0.4
+0.8
(p   0.011 and  (p   0.027
 0.001)  and  0.040)
(Edelman et al 2006) 296 DB, PC, multicenter 29 30–60 µg tid or 
placebo
–0.5
–0.5
–1.3
+1.2
(p   0.0001)
aThese data were extrapolated from graphs, because the absolute values were not reported in the test of the published studies.
Note: Fineman 1999, Whitehouse 2002, Ratner 2004 studies – subjects with entry HbA1c between 7.0 and 8.5% (n = 477) are summarized in Ratner et al 2005.
Abbreviations: DB, double-blind; MC, multicenter; PC, placebo-controlled; R, randomized; RCT, randomized control trials.Vascular Health and Risk Management 2008:4(2) 358
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who were close to recommended glycemic targets (Hollander 
et al 2003a). In these studies patients using pramlintide 
needed proportionally lower doses of total daily insulin. As 
demonstrated in the studies of type 1 DM, pramlintide does 
not require β cell function to exhibit its full glucose lowering 
effect. Therefore, it is can also be used in a population with 
advanced type 2 DM who have reduced β cell function.
Effect on body weight
Improvement in glycemic control and associated increase 
in body weight is well-known (Purnell and Weyer 2003; 
Hoogwerf 2006). In UKPDS, weight gain was noted to be 
greater in the intensive policy group compared to the conven-
tional policy group (UKPDS Research Group 1998a,b) and 
occurred not only with insulin and sulphonylureas but also 
with metformin. Participants in the conventional policy group 
also gained weight. The gain occurred in all groups despite 
patients receiving dietary advice from a dietitian to maintain 
a near normal weight. In fact the dietary efforts, including 
recommendation for a calorie- restricted diet, were imple-
mented 3 months prior to randomization and were continued 
throughout the trial. This implies that dietary modiﬁ  cation, 
albeit very important, is not sufﬁ  cient to limit weight gain. 
Weight gain is a well known barrier to the treatment of type 
2 DM, especially in patients who are overweight or obese. 
Such patients may actually avoid achieving glycemic target to 
prevent accrual of additional pounds. The etiology of weight 
gain with improved glycemic control is likely to be multi 
faceted – reduction in glucosuria, increased caloric intake to 
avoid hypoglycemia, and anabolic effect of insulin on adipose 
tissue (Purnell and Weyer 2003). It has been estimated that 
patients gain about 2 kg (4.4 lbs) for every 1% reduction in 
Hba1c (Purnell and Weyer 2003).
The addition of pramlintide to adjuvant insulin causes 
weight loss in a majority of people. Of note, the initial studies 
were not designed to be weight loss trials. But a post-hoc anal-
ysis involving 2 large studies that included over 240 patients 
in each arm showed a placebo corrected reduction in body 
weight of 0.41% and 1.8 kg (p   0.0001) (Hollander et al 
2004). Weight loss is moderate in overweight and moderately 
obese patients and occurs in spite of a reduction in HbA1c. 
This is in striking contrast to weight gain with intensiﬁ  ca-
tion of insulin therapy. Weight loss is more pronounced in 
patients with severe obesity and occurs regardless of whether 
patients experience nausea, conﬁ  rming the notion that the 
weight reduction is not simply a secondary consequence 
of nausea. Hollander also noted that pramlintide seemed to 
have somewhat greater weight lowering effect in patients 
Table 3 Studies of pramlintide use in patients with type 2 DM
Study Pat (n) Study Design Duration 
(weeks)
Pramlintide dose ∆ HbA1c (%) ∆ Weight (kg)
(Thompson 
et al 1998)
203 MC, R, DB, PC 4 Placebo
30 µg qid
–0.27
–0.53*
–0.04
–0.36
60 µg tid –0.58* –0.89**
60 µg qid –0.51* –0.72**
(Gottlieb 
et al 2007)
499 MC, DB, PC 26 Placebo
90 µg bid
–0.1
–0.3
0.1
–0.8
90 µg tid –0.4 –1.3
120 µg bid –0.4* –1.4
(Ratner et al 
2005)
538 MC, R, DB, PC 52 Placebo
30 µg tid
–0.2c
–0.3c
1.0c
–0.3c
75 µg tid –0.5c –0.4*c
150 µg td –0.6*,c –1.2*c
(Hollander 
et al 2003b)ª
656 MC, R, DB, PC 52 Placebo
60 µg tid
–0.25c
– b
+0.7
– b
90 µg bid –0.35 –0.5
120 µg bid –0.62* –1.4*
(Hollander 
et al 2004)
498 Post hoc analysis of 2 
RCTd
26 Placebo 120 µg bid –0.41*** –1.8***
ªSubset of this population with lower HbA1c values also published (Hollander et al 2003a).
bExcluded after efﬁ  cacy analyses after results from another study (not identiﬁ  ed) indicated that this dose was less effective.
cThese data were extrapolated from graphs, because the absolute values were not reported in the test of the published studies.
dGottlieb et al (1999), Hollander et al (2004).
*p   0.05; **p   0.01; ***p   0.0001.
Abbreviations: DB, double-blind; MC, multicenter; PC, placebo-controlled; R, randomized; RCT, randomized control trials.Vascular Health and Risk Management 2008:4(2) 359
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concomitantly treated with metformin (placebo-corrected 
treatment difference at week 26: –2.5 vs 1.6 kg in subjects 
not concomitantly treated with metformin), but the authors 
advise caution in the interpretation of the results because of 
the relatively small sample size and the post-hoc nature of 
the analyses (Hollander et al 2004).
Weight control/loss mechanisms 
and studies
The exact mechanism of amylin mediated weight loss remains 
undeﬁ  ned. In rodents, amylin has been shown to dose depend-
ently reduce food intake and body weight by affecting the 
size and duration of meals. This mechanism appears to be 
centrally mediated and is independent of gastric emptying 
(Lutz et al 1995; Weyer et al 2001; Schmitz et al 2004). High 
density amylin sites have been identiﬁ  ed in the dorsal raphe 
and nucleus acumbens, two brain regions that control feeding 
behavior (Weyer et al 2001).
Pramlintide’s effect on appetite targets peripheral 
episodic satiety signals (Halford 2006) and as such is 
similar to glucagon-like peptide analogues and peptide 
YY analogues. There is evidence of a satiety effect in 
both rodents, diabetic and non-diabetic human subjects. 
Chapman et al studied 16 diabetic and 14 non-diabetic 
men to determine the effects of pramlintide administration 
(compared to placebo) on satiety and caloric intake from 
an available buffet meal (Chapman et al 2005). Pramlintide 
was associated with earlier satiety and reduced food intake. 
As noted above Hollander has reported weight loss with 
pramlintide administration in obese type 2 diabetes patients 
(Hollander et al 2003a, 2004; Chapman et al 2005). In an 
observational study, Want reported on glycemic control and 
weight changes in 27 subjects with type 2 DM followed 
for several years (Want and Ratner 2006). Subjects whose 
baseline body mass index (BMI) was  25 kg/m2 lost an 
average of 4 kg.
Biomarkers of cardiovascular 
disease
There are only a few studies that have reported on the effects of 
pramlintide on risk factors known or suspected to be associated 
with cardiovascular disease. The favorable effects on appetite 
and weight reduction suggest that there should be consis-
tent effects on blood pressure reduction, dyslipidemia, and 
inﬂ  ammatory/oxidation markers. It should be noted that while 
there is a large body of evidence suggesting that replacement of 
amylin with pramlintide in patients with diabetes provides sig-
niﬁ  cant clinical beneﬁ  ts, more studies are needed to assess the 
effect of pramlintide on complications of diabetes. What follows 
has been reported with amylin and/or pramlintide use.
Blood pressure
Native amylin has been associated with hypertension in 
283 hypertensive patients reported by Kailisam et al (2000). 
These authors concluded that increased concentrations of 
amylin seen in hypertensive patients might be genetically 
mediated rather than assuming any causal relationship. In a 
letter to Diabetologia, Young reported blood pressure results 
in 507 type 2 diabetic subjects with pramlintide use showing 
no differences in systolic or diastolic blood pressure in the 3 
treatment groups (30, 75, or 150 µg tid) compared to placebo 
or any change from baseline during 1 year of treatment (Young 
et al 1999). It does not appear that hypertension has character-
ized pramlintide use in the RCTs. Neither hypertension nor 
marked hypotension are common in clinical practice with 
pramlintide use. At present it does not appear that pramlintide 
has any signiﬁ  cant effect on blood pressure.
Lipids
Thomson has reported on lipid values in 203 type 2 diabetic 
subjects treated with placebo and three different doses of 
pramlintide (30 µg QID; 60 µg TID; 60 µg QID) over a period 
of 4 weeks in a randomized, double blind trial (Thompson 
et al 1998). Median reductions in total cholesterol for the 
four groups were 0 mg/dL, 9 mg/dL, 9 mg/dL, and 14 mg/dL 
respectively. The median reduction in the three pramlintide 
treatment groups was statistically different from baseline. 
Median LDL changes in the 60 µg tid and 60 µg qid were 
8 mg/dL and 10 mg/dL, respectively. These differences also 
reached statistical signiﬁ  cance. However, mean changes for 
the treatment groups were not different than placebo although 
mean percent changes suggest a dose response relationship 
for total cholesterol, LDL cholesterol, and triglycerides 
(Figure 1). Levetan studied 16 patients with type 1 DM and 
showed that after 4 weeks of pramlintide therapy reductions of 
postprandial glucose excursion by 86% and glucagon excur-
sion by 87% were associated with a reduction of triglyceride 
excursion by 72% (Levetan et al 2003). Effects of pramlint-
ide on lipids seem modest. Analyses of lipids in subsets of 
patients who have lost signiﬁ  cant amounts of weight have 
not been published, so it is not clear if these will parallel the 
observations reported with exenatide (Blonde et al 2006).
Markers of oxidation
Oxidized lipoproteins, especially oxidized LDL and down-
stream oxidation products of myeloperoxidase such as Vascular Health and Risk Management 2008:4(2) 360
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dinitrotyrosine have been associated with increased risk for 
cardiovascular disease (Hazen 2000; Shishehbor et al 2003; 
Nicholls and Hazen 2004, 2005). Oxidation has also been 
implicated in the pathogenesis of diabetic microvascular com-
plications (Giugliano et al 1996; Ceriello et al 2005, 2007). 
Pramlintide use has also been associated with a signiﬁ  cant 
reduction in postprandial markers of oxidative stress includ-
ing signiﬁ  cantly reduced postprandial excursions of glucose, 
nitrotyrosine, and oxidized LDL. Pramlintide also prevented a 
decline in total radical-trapping antioxidant parameter (using 
the method reported by Ghiselli called TRAP (Ghiselli et al 
1995) as compared with placebo (p   0.03). These changes 
correlated with reduction in postprandial glycemic control.
Practical considerations
Pramlintide has efﬁ  cacy when used in conjunction with 
preprandial insulin therapy in both type 1 and type 2 DM. 
There is generally a need to reduce insulin requirements 
when pramlintide is initiated. The reduction in insulin is usu-
ally in the range of 20% to 50% of preprandial doses (Ryan 
et al 2005; Want 2006). This adjustment is affected by the 
individual patient’s levels of glycemic control. In patients 
who are generally well controlled and in whom the use of 
pramlintide is not only used to reduce prandial glycemic 
excursion but also to facilitate weight loss, 50% reductions 
in preprandial insulin are advisable. In patients with overall 
suboptimal glycemic control, then continuation of prepran-
dial insulin with only small reductions in dose work well. 
In any case patients need to be warned about the increased 
risk for postprandial hypoglycemia (there is a “black box” 
warning in the package insert) with typical risk occurring 
for about 3 hours after the meal (Hussar 2005). All patients, 
especially those with a history of hypoglycemia, need to be 
instructed to increase the frequency of glucose monitoring to 
detect hypoglycemia. It is important to note that pramlintide 
does not impair the glucagon response to hypoglycemia.
Our experience indicates that initiation of pramlintide 
therapy requires careful instruction even in patients who 
have taken insulin for extended periods of time. The con-
cept that a 15 µg dose corresponds to 2.5 units on an insulin 
syringe intuitively seems to be an easy concept. The instruc-
tions provided with the pramlinitide patient kits review 
syringe related administration in detail. However, review of 
dosing administration by a diabetes educator is advisable. 
Furthermore, many patients have become used to the ease 
of dosing with insulin delivered via pen. Pramlintide has 
recently become available in pen delivery devices. Each of 
these devices has predetermined dosing for pramlintide of 
15, 30, 60, and 120 µg. These pens should simplify pram-
lintide administration.
*
*
*
Figure 1 Mean percent changes in lipid values in 203 type 2 diabetic patients on placebo and 3 different doses of pramlintide for 4 weeks.  Derived from Thompson et al (1998).Vascular Health and Risk Management 2008:4(2) 361
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Want and Ratner have proposed a dose titration in type 
2 diabetes which they report is easier for patients to follow 
(Want and Ratner 2006). Patients with type 1 DM begin with 
12 µg (2 units on insulin syringe) ac and increase by 6 µg 
(1 unit) every 3–7 days until they reach the target dose of 60 
µg. Similarly patients with type 2 diabetes begin with 24 µg 
(4 units) and increase by 12 µg (2 units) until they reach the 
target dose of 120 µg ac. This approach helps to simplify 
instructions with pramlintide vial usage.
One common question raised by patients is whether 
pramlintide can be mixed with insulin so that they can give 
a single injection. Although small short-term studies suggest 
that mixing with insulin does not affect efﬁ  cacy (Weyer et al 
2005), pramlintide is not approved for use when mixed with 
insulin and we routinely recommend giving it as a separate 
injection. The small volume (0.2 mL even with the 120 µg 
dose) is not prohibitive for most patients. Pramlintide pens 
have recently become available which will make dosage 
instruction and administration easier.
Nausea is common with initiation of therapy. Starting 
therapy with low dose (15 µg ac in type 1 DM and 30 µg 
ac in type 2 DM) reduces the risk for nausea. However, our 
experience indicates that a small percentage of subjects have 
intolerable nausea even at low doses. This may be a central 
effect. Nausea is also likely to be more of a problem in 
patients with gastroparesis, which could be made worse by 
any agent affecting gastric emptying. However, pramlintide 
is generally considered to be contraindicated in patients with 
gastroparesis (Hussar 2005) or in patients who are on other 
agents known to have effects on gastric emptying such as the 
alpha glucosidase inhibitors. Except in rare cases, nausea 
usually remits with continued use. Pramlintide has not been 
approved for use in pregnancy as safety in pregnancy has 
not been established.
Pramlintide’s use in the immediate future will continue 
to be as a tool for glycemic control. Future considerations 
are likely to include monotherapy or as an adjunct to other 
medications being developed for weight loss. This potential 
use in weight loss is based on early studies in rodent models 
(Roth et al 2006). Recently, Amylin reported the following on 
their web site: “…positive results from a 24-week proof-of-
concept study with pramlintide, an analog of human amylin, 
and recombinant human leptin (r-metHuLeptin; metreleptin) 
combination treatment in overweight or obese subjects. 
At study end, pramlintide/metreleptin treatment reduced 
body weight on average by 12.75%, signiﬁ  cantly more 
than treatment with pramlintide alone (8.4%; p   0.001).” 
(http://investors.amylin.com/phoenix.zhtml). In spite of these 
observations, the long-term effects of pramlintide on weight 
are not known.
Abbreviations
DM, diabetes mellitus; DB, double blind; LDL, low density 
lipoprotein; HDL, high density lipoprotein; MC, multicenter; 
RCT, randomized clinical trial.
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